Molecular subtyping of endometrial carcinoma cell lines uncovers subtype-specific targetable vulnerabilities

Endometrial carcinoma (EC), the most common gynecologic cancer type in developed countries, encompasses four molecular subtypes (POLEmut, MMRd, p53abn, and NSMP) that have prognostic values and guide treatment decisions. Additionally, dual loss of ARID1A and ARID1B (referred to as ARID1A/B) characterizes a significant portion of dedifferentiated/undifferentiated EC (DD/UDEC), a rare but highly aggressive subtype of EC. To advance the translational research for ECs, we analyzed the genomic features of a panel of 39 EC cell lines, leading to the identification of cell lines representing each of these EC molecular subtype. Histologic and immunohistochemical analyses of xenografted tumors from these cell lines confirmed their resemblance of cognate primary EC molecular subtypes. Further investigation of the publicly available genome-wide CRISPR screen data for EC cell lines identified multiple specific genetic dependencies in MMRd, p53abn, and ARID1A/B-dual deficient EC cell lines. Particularly, ARID1A/B-dual deficient DD/UDEC cells selectively rely on mitochondrial oxidative phosphorylation in vitro and in vivo. Therefore, through molecular subtyping of EC cell lines and subsequent characterization of molecular subtype-specific genetic dependencies, our study provides a framework that guides the utility of the EC cell line models for accelerating translational research in EC.

Authors

Institutions

Publication Details

Journal
npj Precision Oncology
Published
2025-07-24
DOI
https://doi.org/10.1038/s41698-025-01053-x
Citations
3
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
4.56

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Molecular subtyping of endometrial carcinoma cell lines uncovers subtype-specific targetable vulnerabilities

Yoon‐La Choi, Bryan T. Hennessy, Mark Carey, Bengul Gokbayrak et al.
3 citations
npj Precision Oncology
Prostate Cancer Treatment and Research
4.56
article

Molecular subtyping of endometrial carcinoma cell lines uncovers subtype-specific targetable vulnerabilities

Yoon‐La Choi, Bryan T. Hennessy, Mark Carey, Bengul Gokbayrak, Spencer D. Martin, Shary Chen, David Huntsman, Eunice Li, Lynn Hoang, Rebecca Ho, Ramon I. Klein Geltink, Janine Senz, Chae Young Shin, Eric Yang, Yemin Wang, Ran Tao, Betty Yao, L. A. Y. Johnston
article en
3 citations

Abstract

Endometrial carcinoma (EC), the most common gynecologic cancer type in developed countries, encompasses four molecular subtypes (POLEmut, MMRd, p53abn, and NSMP) that have prognostic values and guide treatment decisions. Additionally, dual loss of ARID1A and ARID1B (referred to as ARID1A/B) characterizes a significant portion of dedifferentiated/undifferentiated EC (DD/UDEC), a rare but highly aggressive subtype of EC. To advance the translational research for ECs, we analyzed the genomic features of a panel of 39 EC cell lines, leading to the identification of cell lines representing each of these EC molecular subtype. Histologic and immunohistochemical analyses of xenografted tumors from these cell lines confirmed their resemblance of cognate primary EC molecular subtypes. Further investigation of the publicly available genome-wide CRISPR screen data for EC cell lines identified multiple specific genetic dependencies in MMRd, p53abn, and ARID1A/B-dual deficient EC cell lines. Particularly, ARID1A/B-dual deficient DD/UDEC cells selectively rely on mitochondrial oxidative phosphorylation in vitro and in vivo. Therefore, through molecular subtyping of EC cell lines and subsequent characterization of molecular subtype-specific genetic dependencies, our study provides a framework that guides the utility of the EC cell line models for accelerating translational research in EC.

npj Precision OncologyVol. 9(1)
Vancouver Coastal Health (CA), University of British Columbia (CA), Royal College of Surgeons in Ireland (IE), Spinal Cord Injury BC (CA), BC Children's Hospital (CA)
VGH and UBC Hospital Foundation, Canadian Cancer Society, Terry Fox Research Institute, University of British Columbia, Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada
Openalex Percentile: Top 5%
Prostate Cancer Treatment and Research
4.56
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.